This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2004 Jun;23(6):593-4; author reply 594.

doi: 10.1097/00006454-200406000-00030.

Safety of cold-adapted live influenza vaccine

W Paul Glezen, Pedro A Piedra, Ira M Longini, M Elizabeth Halloran

PMID: 15194854
DOI: 10.1097/00006454-200406000-00030

Comparative Study

Safety of cold-adapted live influenza vaccine

W Paul Glezen et al. Pediatr Infect Dis J. 2004 Jun.

. 2004 Jun;23(6):593-4; author reply 594.

doi: 10.1097/00006454-200406000-00030.

Authors

W Paul Glezen, Pedro A Piedra, Ira M Longini, M Elizabeth Halloran

PMID: 15194854
DOI: 10.1097/00006454-200406000-00030

No abstract available

PubMed Disclaimer

Comment on

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM. Bergen R, et al. Pediatr Infect Dis J. 2004 Feb;23(2):138-44. doi: 10.1097/01.inf.0000109392.96411.4f. Pediatr Infect Dis J. 2004. PMID: 14872180 Clinical Trial.

Similar articles

Cold-adapted, live attenuated intranasal influenza virus vaccine.
Zangwill KM. Zangwill KM. Pediatr Infect Dis J. 2003 Mar;22(3):273-4. doi: 10.1097/01.inf.0000057440.24094.ac. Pediatr Infect Dis J. 2003. PMID: 12634591 Review. No abstract available.
Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD. Vesikari T, et al. Pediatrics. 2008 Mar;121(3):e568-73. doi: 10.1542/peds.2007-1405. Epub 2008 Feb 25. Pediatrics. 2008. PMID: 18299305 Clinical Trial.
Cold-attenuated live influenza vaccines, a risk-benefit assessment.
Pfleiderer M, Löwer J, Kurth R. Pfleiderer M, et al. Vaccine. 2001 Dec 12;20(5-6):886-94. doi: 10.1016/s0264-410x(01)00386-3. Vaccine. 2001. PMID: 11738754 Review.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M. Belshe RB, et al. J Pediatr. 2000 Feb;136(2):168-75. doi: 10.1016/s0022-3476(00)70097-7. J Pediatr. 2000. PMID: 10657821 Clinical Trial.
[Live cold-adapted influenza vaccine: state-of-the-art].
Gendon IuZ. Gendon IuZ. Vopr Virusol. 2011 Jan-Feb;56(1):4-17. Vopr Virusol. 2011. PMID: 21427948 Review. Russian.

See all similar articles

Cited by

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP. Piedra PA, et al. Pediatrics. 2005 Sep;116(3):e397-407. doi: 10.1542/peds.2004-2258. Pediatrics. 2005. PMID: 16140685 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information